Latest Period
Q4 2025
Security Snapshot
Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) Institutional Ownership
CUSIP: 03843E104
13F Institutional Holders and Ownership History from Q3 2018 to Q1 2026
Institutions Reporting
176
Shares (Excl. Options)
72,195,502
Price
$6.46
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, $0.001 par value
- Symbol
- AQST on Nasdaq
- Shares outstanding
- 120,192,308
- Price per share
- $4.08
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 72,195,502
- Total reported value
- $466,240,119
- % of total 13F portfolios
- 0%
- Share change
- +4,942,091
- Value change
- +$33,959,561
- Number of holders
- 176
- Price from insider filings
- $4.08
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value is tracked under CUSIP 03843E104.
- 176 institutions reported positions in Q4 2025.
- 4 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 176 to 45 between Q4 2025 and Q1 2026.
- Reported value moved from $466,240,119 to $19,261,324.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 176 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 03843E104?
CUSIP 03843E104 identifies AQST - Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03843E104:
Significant Owners of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BRATTON DOUGLAS K | 11% | $28,720,687 | 10,077,434 | BRATTON DOUGLAS K | 31 Dec 2024 | |||
| BlackRock, Inc. | 5.3% | $35,923,900 | 6,426,343 | BlackRock, Inc. | 30 Sep 2025 | |||
| RTW INVESTMENTS, LP | 5.2% | $34,937,500 | 6,250,000 | RTW Investments, LP | 30 Sep 2025 | |||
| Venrock Healthcare Capital Partners III, L.P. | 2.9% | $7,494,890 | 2,629,786 | Venrock Healthcare Capital Partners III, L.P. | 31 Dec 2024 |
As of 31 Dec 2025, 176 institutional investors reported holding 72,195,502 shares of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST). This represents 60% of the company’s total 120,192,308 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) together control 49% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Bratton Capital Management, L.P. | 8.2% | 9,810,958 | 0% | 100% | $63,378,789 |
| BlackRock, Inc. | 6.5% | 7,775,402 | +19% | 0% | $50,229,098 |
| RTW INVESTMENTS, LP | 5.2% | 6,250,000 | 0% | 0.4% | $40,375,000 |
| VANGUARD GROUP INC | 4.9% | 5,892,334 | +4.1% | 0% | $38,064,478 |
| EcoR1 Capital, LLC | 2.2% | 2,625,000 | 0% | 0.78% | $16,957,500 |
| SAMSARA BIOCAPITAL, LLC | 2.1% | 2,500,000 | 0% | 1.7% | $16,150,000 |
| STATE STREET CORP | 2% | 2,462,778 | +54% | 0% | $15,909,546 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 2,368,092 | +13% | 0% | $15,301,373 |
| FEDERATED HERMES, INC. | 1.7% | 2,032,822 | +159% | 0.02% | $13,132,030 |
| MORGAN STANLEY | 1.5% | 1,758,750 | +25% | 0% | $11,361,525 |
| MILLENNIUM MANAGEMENT LLC | 1.3% | 1,535,369 | +19% | 0.01% | $9,918,484 |
| BANK OF AMERICA CORP /DE/ | 1% | 1,207,591 | -1.2% | 0% | $7,801,038 |
| WELLS FARGO & COMPANY/MN | 0.99% | 1,188,531 | +805% | 0% | $7,677,910 |
| BNP PARIBAS FINANCIAL MARKETS | 0.97% | 1,171,675 | 0% | 0% | $7,569,020 |
| Janney Montgomery Scott LLC | 0.91% | 1,093,210 | -0.6% | 0.02% | $7,062,000 |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.85% | 1,019,792 | -3.7% | 0.01% | $6,587,851 |
| HRT FINANCIAL LP | 0.83% | 994,966 | +78% | 0.02% | $6,427,000 |
| Sio Capital Management, LLC | 0.83% | 993,095 | -34% | 1.1% | $6,415,394 |
| Balyasny Asset Management L.P. | 0.81% | 970,939 | 0.01% | $6,272,266 | |
| D. E. Shaw & Co., Inc. | 0.78% | 941,197 | +3591% | 0% | $6,080,132 |
| GOLDMAN SACHS GROUP INC | 0.76% | 909,064 | +130% | 0% | $5,872,554 |
| Aberdeen Group plc | 0.67% | 809,203 | +29% | 0.01% | $5,227,451 |
| PERCEPTIVE ADVISORS LLC | 0.62% | 747,193 | -80% | 0.09% | $4,826,867 |
| NORTHERN TRUST CORP | 0.62% | 742,794 | +8.8% | 0% | $4,798,450 |
| WASATCH ADVISORS LP | 0.57% | 681,240 | -5.9% | 0.03% | $4,400,810 |
Institutional Holders of Aquestive Therapeutics, Inc. - Common Stock, $0.001 par value (AQST) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 4,641,229 | $19,261,324 | -$3,571,376 | $4.15 | 45 |
| 2025 Q4 | 72,195,502 | $466,240,119 | +$33,959,561 | $6.46 | 176 |
| 2025 Q3 | 66,072,635 | $369,385,999 | +$106,443,073 | $5.59 | 151 |
| 2025 Q2 | 47,601,655 | $157,593,347 | +$12,692,456 | $3.31 | 115 |
| 2025 Q1 | 44,051,858 | $127,751,552 | -$2,587,459 | $2.90 | 120 |
| 2024 Q4 | 43,378,481 | $154,428,036 | -$13,648,629 | $3.56 | 113 |
| 2024 Q3 | 46,754,842 | $232,438,651 | +$19,226,897 | $4.98 | 116 |
| 2024 Q2 | 42,397,820 | $110,236,742 | -$9,111,350 | $2.60 | 95 |
| 2024 Q1 | 41,491,141 | $176,751,489 | +$88,086,384 | $4.26 | 96 |
| 2023 Q4 | 23,788,793 | $48,053,747 | +$1,931,780 | $2.02 | 57 |
| 2023 Q3 | 13,082,950 | $20,018,501 | +$5,799,587 | $1.53 | 45 |
| 2023 Q2 | 19,076,504 | $31,486,971 | +$6,895,297 | $1.65 | 54 |
| 2023 Q1 | 14,936,175 | $17,026,675 | +$181,515 | $1.14 | 34 |
| 2022 Q4 | 14,914,775 | $13,452,963 | -$924,306 | $0.90 | 34 |
| 2022 Q3 | 15,885,912 | $18,581,000 | -$701,258 | $1.17 | 41 |
| 2022 Q2 | 16,697,754 | $10,681,727 | -$1,110,269 | $0.64 | 37 |
| 2022 Q1 | 15,540,728 | $40,562,854 | -$1,905,712 | $2.61 | 49 |
| 2021 Q4 | 16,159,821 | $62,860,046 | +$1,542,125 | $3.89 | 50 |
| 2021 Q3 | 14,777,244 | $64,430,510 | -$3,394,828 | $4.36 | 44 |
| 2021 Q2 | 15,624,060 | $62,031,877 | -$6,395,474 | $3.97 | 56 |
| 2021 Q1 | 16,607,064 | $86,353,974 | -$13,347,120 | $5.20 | 62 |
| 2020 Q4 | 19,140,719 | $102,400,992 | -$3,894,598 | $5.35 | 65 |
| 2020 Q3 | 19,883,853 | $96,529,634 | +$6,732,727 | $4.85 | 57 |
| 2020 Q2 | 18,511,676 | $89,959,616 | +$16,355,927 | $4.86 | 56 |
| 2020 Q1 | 15,971,551 | $35,033,099 | -$11,294,638 | $2.19 | 42 |
| 2019 Q4 | 17,453,204 | $101,100,262 | +$20,834,844 | $5.82 | 55 |
| 2019 Q3 | 13,582,404 | $43,193,449 | -$3,717,359 | $3.18 | 34 |
| 2019 Q2 | 14,515,951 | $60,964,876 | -$1,002,690 | $4.20 | 39 |
| 2019 Q1 | 14,418,719 | $99,632,199 | +$442,125 | $6.91 | 49 |
| 2018 Q4 | 14,369,495 | $90,526,000 | -$232,037,542 | $6.30 | 35 |
| 2018 Q3 | 16,085,145 | $281,645,000 | +$281,645,001 | $17.51 | 44 |